Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.

@article{Matsuguma2006MolecularMF,
  title={Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.},
  author={Kyoko Matsuguma and Seiji Ueda and Sho-ichi Yamagishi and Yuriko Matsumoto and Utako Kaneyuki and Ryo Shibata and Toshiko Fujimura and Hidehiro Matsuoka and Masumi Kimoto and Seiya Kato and Tsutomu Imaizumi and Seiya Okuda},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2006},
  volume={17 8},
  pages={
          2176-83
        }
}

• Kyoko Matsuguma, Seiji Ueda, +9 authors Seiya Okuda
• Published in
  Journal of the American Society of Nephrology…
  2006

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase. ADMA is generated by protein methyltransferase (PRMT) and is metabolized mainly by dimethylarginine dimethylaminohydrolase (DDAH). ADMA levels are reported to increase in patients with chronic kidney disease (CKD), thereby playing a role in the pathogenesis of accelerated atherosclerosis in this population. However, the precise mechanism underlying ADMA accumulation in these patients is not fully understood… CONTINUE READING

Save to Library

Create Alert

Cite

View Paper